Expertise in
16
conditions

Tsunekazu Mizushima

Tochigi, JP 
Expertise in
16
conditions
Tochigi, JP 
OverviewLocationsClinical Research

Overview

Tsunekazu Mizushima practices in Tochigi, Japan. Mizushima is highly rated in 16 conditions, according to our data. Their top areas of expertise are Colorectal Cancer, Viral Gastroenteritis, Crohn's Disease, Endoscopy, and Ileostomy.

Their clinical research consists of co-authoring 363 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Tochigi, Japan
Other Locations
Osaka, 5430035, Japan
Mibu, Japan
Tennojicho-kita, 5438502, Japan
Hori, 5430035, Japan
Suita, Japan
Kyoto, Japan
Kitayama, 5430035, Japan
Sakai, 5918025, Japan
Toyonaka, 5608531, Japan
Kawasaki, 2100821, Japan
Tokyo, 1058512, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer
A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer
Enrollment Status: Unknown
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drugs: Trifluridine, Tipiracil
Study Phase: Phase 3
A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support
A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Enrollment Status: Completed
Publish Date: August 04, 2020
Intervention Type: Drug, Device
Study Phase: Phase 3
View 1 Less Clinical Trial

363 Total Publications

OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation.
OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation.
Journal: Science immunology
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mizushima's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile